Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Tara L Knotts, Shaker A Mousa

Abstract

While substantial evidence supports the use of standard-duration injectable anticoagulants for venous thromboembolism (VTE) prophylaxis, consensus is mixed about which agents may be preferred in acutely ill patients with ongoing need of VTE prophylaxis past the first 10-day duration of hospital stay and post-discharge. Non-vitamin K antagonist oral anticoagulants (NOACs) provide Factor Xa inhibition to prevent the thrombin generation essential in thromboembolism development, but evidence for the efficacy and safety of most NOACs is conflicting regarding extended-duration prophylaxis. Enoxaparin, a preferred injectable anticoagulant in standard-duration VTE prophylaxis, has shown an increased risk of major bleeding events when used in extended-duration prophylaxis, which outweighs its benefit. Rivaroxaban has demonstrated efficacy in extended-duration prophylaxis, but both rivaroxaban and apixaban have shown increased risks of major bleeding. Betrixaban remains the only NOAC approved in the USA for extended-duration VTE prophylaxis, and it demonstrates efficacy, with fewer adverse effects than other NOACs. This review evaluates the appropriateness of different NOAC agents compared with current therapies for the extended-duration...Continue Reading

References

Jun 14, 2001·Archives of Internal Medicine·J AttiaW H Geerts
Aug 30, 2003·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Raza AlikhanAlexander G G Turpie
Aug 4, 2004·Circulation·Alain LeizoroviczUNKNOWN PREVENT Medical Thromboprophylaxis Study Group
Dec 16, 2004·Circulation·Alain Leizorovicz, Patrick Mismetti
Apr 2, 2010·American Journal of Preventive Medicine·Michele G BeckmanThomas L Ortel
Jul 14, 2010·Annals of Internal Medicine·Russell D HullUNKNOWN EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) stud
Aug 27, 2010·Clinical Medicine & Research·David R KumarSteven H Yale
Mar 26, 2011·Chest·Alex C SpyropoulosUNKNOWN IMPROVE Investigators
Nov 2, 2011·Annals of Internal Medicine·Amir QaseemUNKNOWN Clinical Guidelines Committee of the American College of Physicians
Nov 15, 2011·The New England Journal of Medicine·Samuel Z GoldhaberUNKNOWN ADOPT Trial Investigators
Mar 15, 2012·Chest·Gordon H GuyattUNKNOWN American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel
Feb 8, 2013·The New England Journal of Medicine·Alexander T CohenUNKNOWN MAGELLAN Investigators
May 28, 2013·BMJ Quality & Safety·Brandyn D Lau, Elliott R Haut
Aug 21, 2013·International Journal of Critical Illness and Injury Science·Sarah M Adriance, Claire V Murphy
Aug 24, 2013·Expert Opinion on Investigational Drugs·Michael PalladinoLynda Thomson
Dec 19, 2013·Future Cardiology·Noel C ChanJohn W Eikelboom
Jan 18, 2014·Clinics in Colon and Rectal Surgery·Jonathan Laryea, Bradley Champagne
Oct 11, 2014·Thrombosis and Haemostasis·UNKNOWN ISTH Steering Committee for World Thrombosis Day
Jul 15, 2015·Vascular Health and Risk Management·Noel C ChanJohn W Eikelboom
Sep 1, 2015·Vascular Health and Risk Management·Andrew Blann
May 28, 2016·The New England Journal of Medicine·Alexander T CohenUNKNOWN APEX Investigators
Feb 15, 2017·Circulation·Daniel J QuinlanRobert G Hart
Jan 1, 2016·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Eduardo RamacciottiJawed Fareed
Apr 15, 2018·American Heart Journal·C Michael GibsonRobert A Harrington
Apr 17, 2018·The American Journal of Medicine·Gerald ChiSamuel Z Goldhaber
May 11, 2018·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Paul J DavisGeraldine P Schechter
Jul 25, 2018·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alicia ShugartAlexander J Kallen
Aug 28, 2018·The New England Journal of Medicine·Alex C SpyropoulosUNKNOWN MARINER Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.